Study Reveals Ampion’s Gene Regulation Mimics The Anti-inflammatory Results Of Steroids, However With Out Opposed Results

Tuesday, April 20, 2021 Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Michael Macaluso

ENGELWOOD — Ampio Pharmaceuticals (NYSE American: AMPE) introduced findings from preclinical analysis exhibiting that Ampio’s lead drug candidate, Ampion, has a number of the similar anti-inflammatory results because the steroid dexamethasone, however with out the numerous uncomfortable side effects related to steroids.

“Steroids such as dexamethasone are globally immunosuppressive, for both the innate and adaptive immune systems, with effects that are beneficial in the short term and often detrimental in the long term,” mentioned David Bar Ordirector and founding father of Ampio Pharmaceuticals.

“Our study looked at the gene-level interactions of both Ampion and dexamethasone in immunostimulated peripheral blood monocytes, or PBMCs, and it became apparent that Ampion regulated some of the same inflammation-related genes as dexamethasone, albeit through dissimilar mechanisms of action.

“This may explain Ampion’s ability to mimic the anti-inflammatory effects of steroids without producing similar adverse effects.”

“The coronavirus pandemic has highlighted the critical need for medical innovation,” he mentioned Michael MacalusoPresident and CEO of Ampio.

“The potential availability of an anti-inflammatory therapy that provides many of the same benefits of dexamethasone without the similar adverse effects of long-term use would be a boon to patients suffering from a debilitating and often life-threatening inflammatory disease.”

The examine revealed the primary similarities and variations between Ampion and dexamethasone.

agreements between Ampion and Dexamethasone

In the three completely different immunostimulation situations used to guage the impact of Ampion on PBMCs, Ampion upregulated 102 of the identical transcripts as dexamethasone in keeping with RNA sequencing and differential gene expression evaluation carried out with Ingenuity Pathway Analysis (IPA) software program from QIAGEN Digital Insights.

Furthermore, total IPA modeling predicted considerably comparable regulation of downstream molecules by dexamethasone and Ampion based mostly on directionally correlated transcripts. A comparability confirmed that, in every immunostimulatory situation, transcripts regulated by Ampion considerably overlapped with transcripts regulated by dexamethasone.

“Ampion acts as an anti-inflammatory drug with a number of important overlapping effects also provided by dexamethasone,” Bar-Or mentioned.

However, there have been some vital variations between Ampion and dexamethasone. Based on IPA laptop modeling, there have been 30 transcripts through which Ampion’s exercise differed from recognized regulation by dexamethasone – regulating up when dexamethasone was down, or vice versa – in a minimum of one of many remedy situations.

Dexamethasone additionally targets all kinds of molecules not regulated by Ampion.

“These observations, in addition to the different mechanisms of action of the two drugs, may help explain why patients treated with Ampion do not experience the same adverse effects as patients treated with dexamethasone,” Bar-Or mentioned.

“Essentially, this evidence suggests that Ampion is an anti-inflammatory drug with some important overlapping effects of dexamethasone, but without the significant side effects associated with steroids.”